GLP-3 RT (GLP-1/GIP/GCGR)

GLP-3 RT is a 39-amino acid triple agonist peptide that simultaneously targets GLP-1, GIP, and glucagon (GCGR) receptors. Its C18 fatty diacid side-chain modification extends circulating half-life by promoting albumin binding, enabling sustained receptor engagement in preclinical models. Triple incretin agonism represents a mechanistic advance over single- and dual-receptor approaches, and GLP-3 RT is currently under evaluation in Phase 2 clinical trials.

Key Research Findings:

• Rodent studies demonstrated up to 24% body weight reduction in diet-induced obesity (DIO) models over 28 days
• Triple agonism produced ~40% greater metabolic improvement compared to GLP-1-only analogs in preclinical head-to-head comparisons
• In vitro receptor binding assays confirmed balanced nanomolar-range affinity across all three incretin receptors (EC50 < 10 nM)
• Pharmacokinetic profiling showed a ~5-fold extension in half-life versus unmodified peptide controls

For laboratory and research use only.